Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/140738
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGriñán Ferré, Christian-
dc.contributor.authorVasilopoulou, Foteini-
dc.contributor.authorAbás Prades, Sònia-
dc.contributor.authorRodríguez-Arévalo, Sergio-
dc.contributor.authorBagan Polonio, Andrea-
dc.contributor.authorSureda, Francesc X.-
dc.contributor.authorPérez, Belén-
dc.contributor.authorCallado, Luis F.-
dc.contributor.authorGarcía-Sevilla, Jesús A.-
dc.contributor.authorGarcía-Fuster, M. Julia-
dc.contributor.authorEscolano Mirón, Carmen-
dc.contributor.authorPallàs i Llibería, Mercè, 1964--
dc.date.accessioned2019-09-23T11:06:39Z-
dc.date.issued2018-11-20-
dc.identifier.issn1933-7213-
dc.identifier.urihttp://hdl.handle.net/2445/140738-
dc.description.abstractAs populations increase their life expectancy, age-related neurodegenerative disorders such as Alzheimer's disease have become more common. I2-Imidazoline receptors (I2-IR) are widely distributed in the central nervous system, and dysregulation of I2-IR in patients with neurodegenerative diseases has been reported, suggesting their implication in cognitive impairment. This evidence indicates that high-affinity selective I2-IR ligands potentially contribute to the delay of neurodegeneration. In vivo studies in the female senescence accelerated mouse-prone 8 mice have shown that treatment with I2-IR ligands, MCR5 and MCR9, produce beneficial effects in behavior and cognition. Changes in molecular pathways implicated in oxidative stress, inflammation, synaptic plasticity, and apoptotic cell death were also studied. Furthermore, treatments with these I2-IR ligands diminished the amyloid precursor protein processing pathway and increased Aβ degrading enzymes in the hippocampus of SAMP8 mice. These results collectively demonstrate the neuroprotective role of these new I2-IR ligands in a mouse model of brain aging through specific pathways and suggest their potential as therapeutic agents in brain disorders and age-related neurodegenerative diseases. Keywords Imidazoline I2 receptors (2-imidazolin-4-yl)phosphonates Behavior Cognition Neurodegeneration Neuroprotection Aging-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherSpringer Verlag-
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1007/s13311-018-00681-5-
dc.relation.ispartofNeurotherapeutics, 2018-
dc.relation.urihttps://doi.org/10.1007/s13311-018-00681-5-
dc.rights(c) American Society for Experimental NeuroTherapeutics, 2018-
dc.sourceArticles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)-
dc.subject.classificationMalaltia d'Alzheimer-
dc.subject.classificationMalalties neurodegeneratives-
dc.subject.classificationEnvelliment-
dc.subject.otherAlzheimer's disease-
dc.subject.otherNeurodegenerative Diseases-
dc.subject.otherAging-
dc.titleBehavioral and Cognitive Improvement Induced by Novel Imidazoline I2 Receptor Ligands in Female SAMP8 Mice-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/acceptedVersion-
dc.identifier.idgrec682992-
dc.date.updated2019-09-23T11:06:40Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid30460457-
Appears in Collections:Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)

Files in This Item:
File Description SizeFormat 
682992.pdf7.41 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.